NSE: IPCALAB | BSE: 524494

Mid-range Performer

Download real time

1438.60 42.60 (3.05%)

199.9K NSE+BSE Volume

NSE 28 Nov, 2025 1:32 PM (IST)

36,497.9

Market Cap

High in industry

Beta 1Year

Very Low volatility

Ipca Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for IPCALAB, BSE:524494 Ipca Laboratories Ltd.

Ipca Laboratories Ltd.

18 Feb 2022

1438.60

3.05%

IPCA Laboratories

Buy: Ipca Laboratories Ltd.

ICICI Securities Limited

...

Ipca Laboratories Ltd. is trading above all available SMAs

Ipca Laboratories Ltd.

10 Jan 2022

1438.60

3.05%

IPCA Laboratories

Buy: Ipca Laboratories Ltd.

ICICI Securities Limited

The Ipca Laboratories stock has been sub-divided from one existing equity share of | 2 each face value into two equity shares of | 1 each face value. The record date for the same is January 11, 2022 while the ex-date for the same is today i.e. January 10, 2022. Consequently, Ipca Lab's share price has dropped to ~| 1099/share from...

Ipca Laboratories Ltd. has an average target of 1595.00 from 3 brokers.

Ipca Laboratories Ltd.

17 Nov 2021

1438.60

3.05%

Q2FY22 Result Update - Weak quarter; outlook remains positive - BUY

Buy: Ipca Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Q4FY22/Q1FY23. Domestic business (45% of total sales) continues to remain on strong footing and should continue to outperform IPM. Strong API capabilities and diversified model benefit IPCA in the current environment. We recommend Buy' rating on the stock with target price of Rs 2,450 based...

ICICI Direct upgraded Ipca Laboratories Ltd. to Buy with a price target of 1660.0 on 17 Nov, 2025.

Ipca Laboratories Ltd.

17 Nov 2021

1438.60

3.05%

IPCA Laboratories

Buy: Ipca Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Maintain BUY due to good traction in domestic formulations and sustainable growth amid some margin pressure in medium term Target Price and Valuation: We value Ipca at | 2490 i.e. 26x P/E on FY23E EPS...

Ipca Laboratories Ltd. has an average target of 1595.00 from 3 brokers.

Ipca Laboratories Ltd.

07 Aug 2021

1438.60

3.05%

Q1FY22 Result Update - High base plays spoilsport for earnings growth - ACCUMULATE

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

We increase our earnings estimates by 6% for FY23E as we upgrade our growth assumptions on India formulations and UK generics. With tailwind in acute therapy products (mainly Anti-infective medicines), we increase our...

Number of FII/FPI investors decreased from 270 to 254 in Sep 2025 qtr

Ipca Laboratories Ltd.

01 Jun 2021

1438.60

3.05%

Q4FY21 Result Update - Swapping lower sales growth with better core margin - Accumulate

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

One-off sales of CQ and HCQS to impact growth and margin in FY22E We increase our earnings estimates by 9.7%/7.7% for FY22E/23E while revenue cut by 3.3%/3.1% in FY22E/FY23E. Expansion in EBITDA margins by 170bps to 25.2% (management guidance of 25.0-25.5%) due to reduction in...

ICICI Direct upgraded Ipca Laboratories Ltd. to Buy with a price target of 1660.0 on 17 Nov, 2025.

Ipca Laboratories Ltd.

31 May 2021

1438.60

3.05%

4Q - an aberration; outlook remains intact

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA)'s 4QFY21 performance was below expectations, weighed by moderation in the Domestic Formulation (DF) segment and API sales. However, IPCA remains on track to deliver healthy mid-teen YoY growth in the Branded Generics segment. Increased business share from the integrated manufacturing value chain and better operating leverage in DF would drive improvement in profitability going forward adjusted for onetime business from Hydroxychloroquine Sulfate (HCQS) in FY21. We lower our EPS estimate by 5%/2% for FY22/FY23E, reflecting a) sales growth constraints in the API/Generics segment and b) an increase in...

Number of FII/FPI investors decreased from 270 to 254 in Sep 2025 qtr

Ipca Laboratories Ltd.

31 May 2021

1438.60

3.05%

IPCA Laboratories

Hold: Ipca Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Domestic formulations comprise 37% of FY21 revenues. The domestic performance has been volatile at times due to presence of anti-malarials in the portfolio. However, with incremental growth in other therapies, especially non-communicable diseases like pain management, cardiodiabetology, etc, the overall portfolio is poised for steady growth. We expect...

Number of FII/FPI investors decreased from 270 to 254 in Sep 2025 qtr

Ipca Laboratories Ltd.

11 Apr 2021

1438.60

3.05%

On a steady footing

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

IPCA has reported sales of ~INR3.8b (7% of sales) in the Branded export segment over the past 12M (down 5% YoY), largely due to the COVID-led disruption. However, with a reduction in daily new cases in the Middle East / West Africa, the segment is expected to see growth recovery....